Kineta Inc (KANT)

[Renee]

KA changed to KANT. Delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

[Awl416]

Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

[TrendTrade2016]

KA...76C TRIGGER...NOW 80C...LETS SEE A DOLLA!

[TrendTrade2016]

KA...76C TRIGGER UP AHEAD

[TrendTrade2016]

KA...MAKING A MOVE

[saigai]

https://www.pharmiweb.com/press-release/2024-07-08/tuhura-biosciences-enters-into-exclusivity-and-right-of-first-offer-agreement-for-kineta-inc-s-kva

[TrendTrade2016]

IN ON THAT DIP FOR THE BOUNCE

[Invest-in-America]

KA: My Lady Friend next door over here in (balmy) San Diego, CA --- an NCAA Champion Platform Diver --- just now (see below) went to research the BOTTOM PRICE for this puppy today.

[Invest-in-America]

KA: I dumped this long ago today, for a loss!! (I was STUPID to buy-into yet more FLUFF news from the Wall Street Casino --- about a so-called potential Cancer-cure drug which, however, has NOT even made it to late Phase-2, let alone Phase-3, human trial results.)

[TIMGZ]

LOSING MONEY HERE, NEED THE TREND TO REVERSE UP

[INV4]

Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences

July 8, 2024

TuHURA has an exclusive right to negotiate to acquire Kineta’s KVA12123 Immuno-Oncology Drug Program

Kineta will receive a $5 million Nonrefundable Payment from TuHURA

KVA12123 is currently in a Phase 1/Phase 2 Clinical Study in the United States

SEATTLE, July 08, 2024 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into an exclusivity and right of first offer agreement (the “Agreement”) with TuHURA Biosciences, Inc. (“TuHURA”), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Pursuant to the Agreement, among other things, Kineta has granted TuHURA an exclusive right to acquire Kineta’s worldwide patents, patent rights, patent applications, product and development program assets, technical and business information, and other rights and assets associated with and derived from its development program related to KVA12123, the Company’s VISTA blocking immunotherapy. This exclusive right shall continue through the first to occur of (a) the execution of any definitive agreement with respect to a potential transaction by TuHURA or one or more of its affiliates and (b) 11:59 PM Eastern Time on October 1, 2024, subject to extension. In consideration for Kineta’s compliance with its obligations set forth in the Agreement, TuHURA will pay Kineta a $5 million nonrefundable payment.

KVA12123 is a novel VISTA blocking monoclonal antibody being evaluated in a Phase 1/Phase 2 clinical trial for patients with advanced solid tumors. The study includes a monotherapy arm with KVA12123 alone, and a combination arm utilizing KVA12123 together with Merck’s anti-PD1 therapy, KEYTRUDA (pembrolizumab). Initial results from this study were reported in April this year at the American Association of Cancer Research. To date, the drug has been well tolerated with no dose limiting toxicities and no cytokine release syndrome. Additional data is expected to be released in the fourth quarter of 2024.

“TuHURA Biosciences is well positioned to advance KVA12123,” said Craig W. Philips, President of Kineta. “TuHURA is a Phase 3 registration stage immuno-oncology company with expertise and deep experience in the field. We believe they will make an excellent partner for this program and in advancing this novel drug program which could provide an important new treatment option for cancer patients.”

About Kineta
Kineta (Nasdaq: KA) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. The company’s immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors, and a preclinical monoclonal antibody targeting CD27. For more information on Kineta, please visit www.kinetabio.com, and follow Kineta on X (formerly Twitter) and LinkedIn.

KVA12123, through the combination of unique epitope binding and an optimized IgG1 Fc region, has demonstrated strong tumor growth inhibition as both a monotherapy or in combination with other checkpoint inhibitors in preclinical models. KVA12123 provides a novel approach to address immune suppression in the TME with a mechanism of action that is differentiated and complementary with T cell focused therapies. KVA12123 may be an effective immunotherapy for many types of cancer including non-small cell lung (NSCLC), colorectal, renal cell carcinoma, head and neck, and ovarian cancer.

In February 2024, Kineta announced a significant corporate restructuring to substantially reduce expenses and preserve cash. The restructuring included a significant workforce reduction and the suspension of enrollment of new patients in its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. Patients currently enrolled in the trial will be permitted to continue to participate. The Company announced the restructuring as a result of certain investors indicating that they would not fulfill their April 2024 funding obligation in the previously disclosed private placement financing. In connection with the restructuring, the Company announced that it is exploring strategic alternatives to maximize stockholder value.

https://forextv.com/top-news/kineta-announces-exclusivity-and-right-of-first-offer-agreement-for-its-vista-blocking-antibody-with-tuhura-biosciences/

$KA

[Invest-in-America]

KA: Many news sources reporting KA's Cancer drug deal today ---
https://forextv.com/top-news/kineta-announces-exclusivity-and-right-of-first-offer-agreement-for-its-vista-blocking-antibody-with-tuhura-biosciences/
https://www.prnewswire.com/news-releases/tuhura-biosciences-enters-into-exclusivity-and-right-of-first-offer-agreement-for-kineta-incs-kva12123-novel-anti-vista-checkpoint-inhibitor-302190378.html

[glenn1919]

KA............................................https://stockcharts.com/h-sc/ui?s=KA&p=W&b=5&g=0&id=p86431144783

[Me2Greedy]

Not too late. Could hit $1 AH

[gail]

im not in this one

[Me2Greedy]

Moving AH on news

[INV4]

Thanks Gail!

HOD 0.74 so far today 😃

$KA

[gail]

its up 17% so ……

….

far today it shows, so im happy for you.

[INV4]

Ok lol 😄 Well I like the Float (6.59M) / OS (10.96M).

(I've seen such an $8 price target with $OCEA when it was trading at $0.50 cents or something and it hit $7.79. I took a small starter here... Whatever happens, it's all good).

KINETA INC (KA):
Shares Outstanding 10.96M
Shares Change (YoY) +124.40%
Shares Change (QoQ) +8.20%
Owned by Insiders (%) 29.25%
Owned by Institutions (%) 12.05%
Float 6.59M

GLTY

$KA

[gail]

moved on to bigger and better things, lol

[INV4]

Have you seen this price target? I don't know if that target is realistic/achievable here?

================

Kineta (KA) Price Target Increased by 25.58% to 13.77
April 17, 2024 — 08:19 pm EDT

The average one-year price target for Kineta (NasdaqCM:KA) has been revised to 13.77 / share. This is an increase of 25.58% from the prior estimate of 10.96 dated March 28, 2024.

The price target is an average of many targets provided by analysts. The latest targets range from a low of 13.64 to a high of 14.18 / share. The average price target represents an increase of 2,770.54% from the latest reported closing price of 0.48 / share.

https://www.nasdaq.com/articles/kineta-ka-price-target-increased-by-25.58-to-13.77

$KA

[gail]

in a good way? i see we are moving up now.

[Awl416]

Watch out

[Awl416]

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

[Monksdream]

KA new 52 week lo

[AJ Freely]

$KA - Up 7% Pre-Market/ Current Price $2.48
To Receive $5 Million Milestone Payment from Merck & eligible to receive additional milestone payments totaling up to $255m associated with the successful development of marketed products for pipeline program | 6/20.23

[makinezmoney]

$KA : Here you go............


https://investorshub.advfn.com/Starry-GROUP-Holdings-41712

Merr Christmas



GO $KA

[tw0122]

Can you get them to open up comments on STRY you have clout.. Lol up over 1,436 percent biggest runner today..

Starry got delisted

[makinezmoney]

$KA: ReverseMerger with Yumanity Thera completed


https://kinetabio.com/

Added 10k here at $4.50 !!!!!!!!!!


LETS GOOooooooooooooooooooooooooooooooooo


The Company
Kineta is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. Kineta’s focus on innate immunity differentiates it from other immuno-oncology companies that are primarily focused on adaptive immunity and T cell focused therapies.
Kineta has established its immuno-oncology focused platform aimed at developing fully human antibodies to address the major mechanisms of cancer immune resistance. With drug candidates expected to enter the clinic and additional immuno-oncology assets in preclinical development, Kineta believes it is positioned to achieve multiple value-driving catalysts.

Kineta has assembled an experienced management team, a seasoned research and development team, an immuno-oncology focused scientific advisory board, an enabling technology platform and a leading intellectual property position to advance its pipeline of potential novel immunotherapies for cancer patients.


GO $KA